Enough Evidence Tying AndroGel To Heart Attacks, Jury Hears

There is enough evidence to connect testosterone therapy drugs to an increased risk of heart attack, a cardiologist testifying in a trial against AbbVie Inc. over its AndroGel product told an...

Already a subscriber? Click here to view full article